Skip to content
Senseonics Holdings, Inc.
 logo

Senseonics Holdings, Inc.

SENS

Senseonics Holdings, Inc. is a medical technology company that develops and commercializes long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes.

Market cap
$261.54M-34.1%
Revenue$40.7M+71.9%
Net income-$87.2M-17.8%
Free cash flow-$75.9M-29.4%
EPS (diluted)-$1.63+1.2%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$13.4M
EPS estimate-$0.61

Financials

Q1 2026

Income statement

See full
Revenue$11.7M+87.2%
Gross profit$6.9M+361%
Operating income-$31.8M-136%
Net income-$32.3M-127%
EPS (diluted)-$0.71-77.5%

Balance sheet

See full
Cash & equivalents$29.6M-24.7%
Total debt$43.1M+5.0%
Total equity$34.3M-2.4%
Total assets$102.9M+17.9%

Cash flow

See full
Operating cash flow-$32.0M-99.2%
CapEx$111.0K-74.4%
Free cash flow-$32.1M-94.6%

Valuation & ratios

Valuation

See full
Market cap$261.54M-34.1%
Enterprise value$275.07M-38.5%
P/S6.4×-10.7×

Profitability

See full
Gross margin52.1%+44.9pp
Operating margin-213%-46.7pp
Net margin-214.1%-51.2pp
FCF margin-186.4%-37.0pp

Returns & leverage

See full
Return on equity-250.7%-19.0pp
Debt / equity1.3×+0.1×
Current ratio3.5×-3.4×

Segments

By segment

See full
Single Reportable$11.7M+87.2%

Competitors

Profile

Senseonics Holdings, Inc. is a medical technology company that develops and commercializes long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its core value proposition is providing a highly accurate, under-the-skin sensor that lasts significantly longer than traditional non-implantable systems, reducing the frequency of sensor replacements and enhancing real-time disease management.

Competitive position

Senseonics is a specialized player in the CGM market, distinguishing itself through the only FDA-approved long-term implantable sensor that lasts up to one year.

GeographiesUnited States, European Economic Area, Italy, Germany, Spain, Sweden
Customer segmentsType 1 diabetes patients, Type 2 diabetes patients, Medicare beneficiaries, Healthcare professionals
Business modelDirect-to-distributor, Consignment, Medical device manufacturing
SuppliersContract manufacturers in North America and Europe, Sterilization service providers, Raw material suppliers for optical systems and hydrogels
CustomersMedical distributors, Strategic fulfillment partners, Healthcare professionals and clinics, Direct-to-consumer patients
Listed2016
Employees132.0
CEOTimothy T. Goodnow
FilingsSEC EDGAR

Questions, answered.

What is Senseonics Holdings, Inc. 's market cap?
Senseonics Holdings, Inc. (SENS) has a market capitalization of $261.5M and trades on AMEX.
What is Senseonics Holdings, Inc. 's revenue and profitability?
Senseonics Holdings, Inc. generated $40.7M in trailing twelve-month revenue with a net loss of $87.2M, representing a net margin of -214.1%. Gross margin stands at 52.1%, with free cash flow of -$75.9M. These figures are based on the Q1 2026 filing.
Who are Senseonics Holdings, Inc. 's competitors?
Senseonics Holdings, Inc. 's key competitors include Abbott, Medtronic, Dexcom, and others. These companies compete in similar markets and product categories.
Who does Senseonics Holdings, Inc. partner with?
Senseonics Holdings, Inc. 's notable partners include Ascensia Diabetes Care Holdings AG, UnitedHealthcare, Abbott Diabetes Care, and others.
What subsidiaries does Senseonics Holdings, Inc. have?
Senseonics Holdings, Inc. 's subsidiaries include Senseonics, Inc., Eon Care.
Where is Senseonics Holdings, Inc. headquartered?
Senseonics Holdings, Inc. is headquartered in United States of America and employs approximately 132 people. It has been publicly traded since 2016.